The Cooper Companies, based in San Ramon, California, employs 15,000 and operates through CooperVision, focused on contact lenses, and CooperSurgical, specializing in fertility and women's health solutions.
Based on our analysis, Cooper Companies has received a fairly valued rating of 2 out of 5 stars from Cashu. This assessment is primarily based on its financial performance in comparison to industry standards.
One noteworthy area where Cooper Companies does not outperform the sector is its Price-to-Earnings (P/E) Ratio, which stands at 36.17 compared to the sector’s average of 13.90. A higher P/E ratio can indicate that the stock is overvalued relative to its earnings, suggesting that investors may be paying a premium for the company's future growth expectations.
Additionally, Cooper Companies has a Dividend Yield of 0.00, significantly lower than the sector average of 0.19. This lack of dividends may deter income-focused investors, who often look for regular returns in the form of dividends.
Another financial metric to consider is the Return on Equity (ROE) Ratio, which is 4.85 for Cooper Companies, while the sector average is -75.69. Although Cooper's ROE is positive, it is relatively modest and indicates that the company generates a lower return on shareholders' equity compared to the broader industry.
These metrics highlight areas where Cooper Companies may be seen as less attractive relative to its peers, contributing to its fair valuation rating. Investors may want to consider these factors when assessing the company’s potential for growth.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!